VaccinesStudies updated this monthMyocarditis after vaccination — a rare exception or an overlooked problem?
Sources: 16 · Article: 22 177 characters ↓
What do Natural Therapy Specialists write?
Stowarzyszenie STOP NOP
Myocarditis and pericarditis were described as the most serious cardiovascular complication after vaccination.
„KÜBLER – Heidelberg, Germany
“(…) The most serious cardiovascular complication is myocarditis and pericarditis. These have been observed not only after smallpox and/or polio vaccines, but also after vaccines against diphtheria and tetanus, as well as whooping cough, cholera and, occasionally, typhoid fever.”KÜBLER – Heidelberg, Niemcy
„(…) Najpoważniejsze powikłanie sercowo-naczyniowe to zapalenie mięśnia sercowego i osierdzia. Obserwowano je nie tylko po podaniu szczepionek przeciwko ospie i/lub polio, ale również przeciwko błonicy i tężcowi, a także kokluszowi, cholerze i czasem durowi brzusznemu.
Stowarzyszenie STOP NOP
Symptoms of myocarditis were observed in 8 of 234 Finnish conscripts, or 3%, within six weeks of several vaccinations.
„Among 234 Finnish conscripts vaccinated against mumps, polio, tetanus, smallpox, diphtheria and meningococcal group A, 8 (3%) showed symptoms of myocarditis within 6 weeks.1 As a rule, vaccine complications occur more often in women, whereas myocarditis occurs more often in men.”Spośród 234 fińskich poborowych szczepionych przeciwko śwince, polio, tężcowi, ospie, błonicy i dwoinkom zapalenia opon mózgowych typu A, u 8 (3%) w ciągu 6 tygodni obserwowano objawy zapalenia mięśnia sercowego.1 Z reguły powikłania poszczepienne występują częściej u kobiet, natomiast zapalenie mięśnia sercowego częściej występuje u mężczyzn.
Stowarzyszenie STOP NOP
Myocarditis occurs more often in men, although other vaccine complications are more common in women.
Stowarzyszenie STOP NOP
Up to 30% of cases of post-vaccination myocarditis have an unfavorable course.
„2 One should not automatically assume that post-vaccination myocarditis is mild: up to 30% of cases have an unfavorable course.3 Fatal complications are not caused only by polio and smallpox vaccines; they have also been observed after vaccines against typhus and cholera.”2 Nie należy automatycznie zakładać, że poszczepienne zapalenie mięśnia sercowego ma charakter łagodny: do 30% przypadków ma przebieg niekorzystny.3 Śmiertelne powikłania nie są spowodowane wyłącznie szczepieniami polio i ospy, obserwowano je również po szczepieniach przeciwko durowi plamistemu i cholerze.
Stowarzyszenie STOP NOP
The STOP NOP Association states that vaccination is associated with myocarditis in 3% of healthy patients.
„?Vaccination causes myocarditis in 3% of healthy patients (Helle, Koskenvuo, Heikkilaet al.1978; Amsel, Hanukoglu, Friedet al.1986). Part of this can be explained by circulating antigen precipitating in the heart tissue however people often develop autoantibodies to myocardial tissue after damage to the heart (Rose, Herskowitz, Neumannet al.1988) and this response may be exacerbated by a vaccine draining into a lymph node where the autoimmune process is developing.”?Vaccination causes myocarditis in 3% of healthy patients (Helle, Koskenvuo, Heikkilaet al.1978; Amsel, Hanukoglu, Friedet al.1986). Part of this can be explained by circulating antigen precipitating in the heart tissue however people often develop autoantibodies to myocardial tissue after damage to the heart (Rose, Herskowitz, Neumannet al.1988) and this response may be exacerbated by a vaccine draining into a lymph node where the autoimmune process is developing.
Stowarzyszenie STOP NOP
The STOP NOP Association describes the possibility of chronic damage to the heart muscle caused by an autoimmune reaction after inflammation.
„In either case the myocarditis induced by vaccination can lead to chronic autoimmune destruction of the myocardial tissue. ?
?Rare association: possible myocarditis secondary to influenza vaccination.? (thefreelibrary.com)
Helv Paediatr Acta 1976 OCT;31(3):257-60 (cbi.nlm.nih.gov/pubmed)
Cardiac complications after vaccination for smallpox (apria.com)
Acute Myocarditis Associated with Tetanus Vaccination?Dilber, Embiya; Karagoz, Tevfik; Aytemir, Kudret; Ozer, Sema; Et al
Amsel SG, Hanukoglu A, Fried D, Wolyvovics M.”In either case the myocarditis induced by vaccination can lead to chronic autoimmune destruction of the myocardial tissue. ?
?Rare association: possible myocarditis secondary to influenza vaccination.? (thefreelibrary.com)
Helv Paediatr Acta 1976 OCT;31(3):257-60 (cbi.nlm.nih.gov/pubmed)
Cardiac complications after vaccination for smallpox (apria.com)
Acute Myocarditis Associated with Tetanus Vaccination?Dilber, Embiya; Karagoz, Tevfik; Aytemir, Kudret; Ozer, Sema; Et al
Amsel SG, Hanukoglu A, Fried D, Wolyvovics M.
Jerzy Zięba
Myocarditis was included on the list of adverse events.
„Guillain-Barré syndrome
acute disseminated encephalomyelitis,
transverse myelitis,
myelitis,
encephalomyelitis,
meningitis,
meningoencephalitis,
narcolepsy and cataplexy
acute myocardial infarction,
myocarditis,
pericarditis,
autoimmune disease,
other acute demyelinating diseases,
non-anaphylactic allergic reactions,
disseminated intravascular coagulation,
venous thromboembolic disease,
arthritis and joint pain,
multisystem inflammatory syndrome in children,
vaccine-enhanced disease.”syndrome Guillain-Barré
ostre rozpowszechnione zapalenie mózgu i rdzenia,
poprzeczne zapalenie rdzenia kręgowego,
zapalenie rdzenia kręgowego,
zapalenie mózgu i rdzenia,
zapalenie opon mózgowo-rdzeniowych,
zapalenie opon mózgowo-rdzeniowych,
narkolepsja i katapleksja
ostry zawał mięśnia sercowego,
zapalenie mięśnia sercowego,
zapalenie osierdzia,
choroba autoimmunologiczna,
inne ostre choroby mielinizacyjne,
nieanafilaktyczne reakcje alergiczne,
rozsiane wykrzepianie wewnątrznaczyniowe,
żylna choroba zakrzepowo-zatorowam,
zapalenie stawów i bóle stawów,
wieloukładowy zespół zapalny u dzieci,
choroba wzmocniona szczepionkami.
Prof. Sucharit Bhakdi
Prof. Sucharit Bhakdi states that spike protein was detected in heart biopsies of patients with myocarditis after vaccination; the cases described involved mRNA and adenovirus vaccines.
„Expression of spike protein in heart muscle cells after COVID-19 vaccination has been documented in heart biopsies of myocarditis patients by Baumeier et al. [133]. Both mRNA and adenovirus-based vaccines were represented among the reported cases. More widespread and apparently stronger expression than reported by Baumeier et al.”Expression of spike protein in heart muscle cells after COVID-19 vaccination has been documented in heart biopsies of myocarditis patients by Baumeier et al. [133]. Both mRNA and adenovirus-based vaccines were represented among the reported cases. More widespread and apparently stronger expression than reported by Baumeier et al.
Prof. Sucharit Bhakdi
Prof. Sucharit Bhakdi also describes a fatal case in which spike protein was detected in tissue, but nucleocapsid was not.
„More widespread and apparently stronger expression than reported by Baumeier et al. was detected by Burkhardt and colleagues in tissue samples from an as yet unpublished fatal case of myocarditis. Here, nucleocapsid expression was also examined but found to be negative, confirming that the expression of spike had been caused by vaccination.”More widespread and apparently stronger expression than reported by Baumeier et al. was detected by Burkhardt and colleagues in tissue samples from an as yet unpublished fatal case of myocarditis. Here, nucleocapsid expression was also examined but found to be negative, confirming that the expression of spike had been caused by vaccination.
Prof. Sucharit Bhakdi
Prof. Sucharit Bhakdi states that the highest risk is among young men, and that the incidence after mRNA COVID-19 vaccines ranged from fewer than 10 to more than 100 cases per million doses.
„The incidence of myocarditis ranged from under 10 cases per million to over 100 cases per million doses of vaccine. Compared to unvaccinated or baseline rates, myocarditis incidence was about two to nearly 30 times greater for the vaccinated, depending on age, sex, and vaccine type.”The incidence of myocarditis ranged from under 10 cases per million to over 100 cases per million doses of vaccine. Compared to unvaccinated or baseline rates, myocarditis incidence was about two to nearly 30 times greater for the vaccinated, depending on age, sex, and vaccine type.
Prof. Sucharit Bhakdi
Prof. Sucharit Bhakdi states that, compared with unvaccinated people or baseline rates, the incidence was about 2 to nearly 30 times higher, depending on age, sex and vaccine type.
„Compared to unvaccinated or baseline rates, myocarditis incidence was about two to nearly 30 times greater for the vaccinated, depending on age, sex, and vaccine type. Rates were usually higher after the second dose than the first. In contrast, COVID-19 infection (defined by positive PCR test) was not associated with either myocarditis (adjusted hazards ratio (aHR) 1.08; 95% CI 0.45-2.56) or pericarditis (aHR 0.53; 95% CI 0.25-1.13) in a large retrospective cohort study of nearly 200,000 adults in Israel between March 2020 and January 2021 [306].”Compared to unvaccinated or baseline rates, myocarditis incidence was about two to nearly 30 times greater for the vaccinated, depending on age, sex, and vaccine type. Rates were usually higher after the second dose than the first. In contrast, COVID-19 infection (defined by positive PCR test) was not associated with either myocarditis (adjusted hazards ratio (aHR) 1.08; 95% CI 0.45-2.56) or pericarditis (aHR 0.53; 95% CI 0.25-1.13) in a large retrospective cohort study of nearly 200,000 adults in Israel between March 2020 and January 2021 [306].
Prof. Sucharit Bhakdi
According to Prof. Sucharit Bhakdi, cases of myocarditis after mRNA vaccines occurred more often after the second dose than after the first.
„Rates were usually higher after the second dose than the first. In contrast, COVID-19 infection (defined by positive PCR test) was not associated with either myocarditis (adjusted hazards ratio (aHR) 1.08; 95% CI 0.45-2.56) or pericarditis (aHR 0.53; 95% CI 0.25-1.13) in a large retrospective cohort study of nearly 200,000 adults in Israel between March 2020 and January 2021 [306].”Rates were usually higher after the second dose than the first. In contrast, COVID-19 infection (defined by positive PCR test) was not associated with either myocarditis (adjusted hazards ratio (aHR) 1.08; 95% CI 0.45-2.56) or pericarditis (aHR 0.53; 95% CI 0.25-1.13) in a large retrospective cohort study of nearly 200,000 adults in Israel between March 2020 and January 2021 [306].
Prof. Sucharit Bhakdi
Prof. Sucharit Bhakdi describes animal studies in which myocarditis after mRNA vaccines was more severe following intravenous than intramuscular administration; he presents a similar course in humans as an assumption.
„In animal studies, it has been observed that myocarditis caused by mRNA vaccines is more severe after intravenous than after intramuscular injection [18]. The same must be assumed to be the case with humans and with damage to other organs, including the brain.”In animal studies, it has been observed that myocarditis caused by mRNA vaccines is more severe after intravenous than after intramuscular injection [18]. The same must be assumed to be the case with humans and with damage to other organs, including the brain.
Prof. Sucharit Bhakdi
Prof. Sucharit Bhakdi describes the heart muscle fibers in the sample examined as separated and breaking down, with immune cells around them.
„The picture on the shows a sample of healthy heart muscle tissue, with regularly oriented and aligned heart muscle fibres. On the right, we see a heart muscle sample from one of the autopsies. The muscle fibres are disjointed and disintegrating, and they are surrounded by invading lymphocytes. Burkhardt found myocarditis in multiple of his deceased patients.”The picture on the shows a sample of healthy heart muscle tissue, with regularly oriented and aligned heart muscle fibres. On the right, we see a heart muscle sample from one of the autopsies. The muscle fibres are disjointed and disintegrating, and they are surrounded by invading lymphocytes. Burkhardt found myocarditis in multiple of his deceased patients.
Prof. Sucharit Bhakdi
Prof. Sucharit Bhakdi states that myocarditis was found in several of the deceased patients included in the study.
What does scientific research from PubMed · Europe PMC say?
We selected 8 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 1 772.
Aim of the study: The incidence of myocarditis after RNA-based vaccines for coronavirus has gained social and medical interest.
Results: We analyzed 17,704,413 subjects, from 7 studies, that included 627 cases of confirmed myocarditis). The incidence of myocarditis was 0.0035% (95% CI 0.0034-0.0035). Mean incidence rate was 10.69 per 100.000 persons-year. Cases reported from Israel represented 45.14% from total (283 out of the 627). Only 1 case of fatal myocarditis or death was reported. There was significant heterogeneity between results. The meta-regression analysis excluded mean age, region, number of cases or number of people included as sources of heterogeneity. No small-study effect was observed (p = 0.19). Myocarditis incidence after RNA vaccines is very rare (0.0035%) and has a very favorable clinical course.
Money for the studynot stated
Do the authors have ties to companies?yes — the authors reported it
Did a manufacturer help with the study?YES
Type of studycombined analysis of many studies (meta-analysis)
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Although myocarditis and pericarditis were not observed as adverse events in coronavirus disease 2019 (COVID-19) vaccine trials, there have been numerous reports of suspected cases following vaccination in the general population.
Results: This compares with an extra 40 (95% CI 38, 41) myocarditis events per 1 million patients in the 28 days following a SARS-CoV-2 positive test. We also observed increased risks of pericarditis and cardiac arrhythmias following a positive SARS-CoV-2 test. Similar associations were not observed with any of the COVID-19 vaccines, apart from an increased risk of arrhythmia following a second dose of mRNA-1273. Subgroup analyses by age showed the increased risk of myocarditis associated with the two mRNA vaccines was present only in those younger than 40.
Money for the studygovernment, public institutions · British Heart Foundation, National Institute for Health Research (NIHR), Medical Research Council
Do the authors have ties to companies?yes — the authors reported it
Did a manufacturer help with the study?YES
Type of studyobservation of people
Participants20 615 911
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Concerns about myocarditis and mortality after COVID-19 vaccination in pediatrics persist despite limited direct comparisons with SARS-CoV-2 infection risks. We compared risks of myocarditis, pericarditis, and mortality between infection and BNT162b2 vaccination in adolescents and young adults.
Results: The infected/unvaccinated group had the highest cumulative incidence of myocarditis (0.116%). After 1:1 propensity-score matching, SARS-CoV-2 infection was associated with significantly higher risks of myocarditis (relative risk [RR] = 4.91; 95%CI = 3.11-7.77), pericarditis (RR = 1.93; 95%CI = 1.39-2.67), and mortality (RR = 1.33; 95%CI = 1.04-1.71) versus no infection. In direct comparison, vaccination was associated with 85% lower myocarditis risk, 79% lower pericarditis risk, and 72% lower mortality versus infection. Protection was consistent across sexes. The absolute risk difference for myocarditis was 0.0354%, corresponding to one fewer recorded myocarditis event per 2827 individuals in the vaccinated/uninfected group compared with the infected/unvaccinated group. Recorded SARS-CoV-2 infection was associated with higher short-term risks of myocarditis, pericarditis, and all-cause mortality than recorded BNT162b2 vaccination in adolescents and young adults.
Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studyobservation of people
Participants4 072 375
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Vaccines have demonstrated protection against the morbidity and mortality of COVID-19, but concerns regarding the rare side effect of acute myocarditis have stymied immunization efforts. This review aims to describe the incidence and theorized mechanisms of COVID vaccine-associated myocarditis and review relevant principles for management of vaccine-associated myocarditis.
Money for the studynot stated · funding
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: SARS-CoV-2 vaccine-associated myocarditis/myocardial injury should be evaluated in the contexts of COVID-19 infection, other types of viral myocarditis, and other vaccine-associated cardiac disorders. COVID-19 vaccine-associated myocardial injury can be caused by an inflammatory immune cell infiltrate, but other etiologies such as microvascular thrombosis are also possible.
Results: These rates equate to excess incidences above control populations of approximately 1.2 (BNT162b2) and 1.9 (mRNA-1273) per 100 000 persons, which are lower than the myocarditis rate for smallpox but higher than that for influenza vaccines. In the studies that have included mRNA vaccine and SARS-COVID-19 myocarditis measured by the same methodology, the incidence rate was increased by 3.5-fold over control in COVID-19 compared with 1.5-fold for BNT162b2 and 6.2-fold for mRNA-1273. However, mortality and major morbidity are less and recovery is faster with mRNA vaccine-associated myocarditis compared to COVID-19 infection. The reasons for this include vaccine-associated myocarditis having a higher incidence in young adults and adolescents, typically no involvement of other organs in vaccine-associated myocarditis, and based on comparisons to non-COVID viral myocarditis an inherently more benign clinical course.
Money for the studygovernment, public institutions · NIAID NIH HHS
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Myocarditis is an established but rare adverse event following administration of messenger RNA-based coronavirus disease 2019 (COVID-19) vaccines and is most common in male adolescents and young adults. Symptoms typically develop within a few days of vaccine administration.
Results: Symptoms typically develop within a few days of vaccine administration. Most patients have mild abnormalities on cardiac imaging with rapid clinical improvement with standard treatment. However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination. The purpose of the review is to evaluate the current literature related to myocarditis following COVID-19 vaccination, including the incidence, risk factors, clinical course, imaging findings, and proposed pathophysiologic mechanisms.
Money for the studygovernment, public institutions · Department of Medicine, University of Toronto, Ministry of Colleges and Universities, Canada Research Chairs
Do the authors have ties to companies?yes — the authors reported it
Did a manufacturer help with the study?YES
Type of studydiscussion of other studies
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Myocarditis and pericarditis are inflammatory conditions of the heart that present a range of symptoms, often including chest pain, fatigue, breathlessness and palpitations that may be irregular due to cardiac rhythm disturbances.
Results: Furthermore, following vaccination with mRNA COVID-19 vaccines (ie, Comirnaty and Spikevax), myocarditis and pericarditis can develop within a few days of vaccination, particularly following the second dose. Based on recent reviewed data, the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have determined that the risk for both of these conditions is overall 'very rare' (~1 in 10 000 vaccinated people may be clinically affected), with the highest risk among younger males. Both EMA and FDA agree that the benefits of all authorised COVID-19 vaccines continue to outweigh their risks, given the threat of serious COVID-19 illness and related complications. Since myocarditis has a very wide clinical spectrum, ranging from mild to fulminant life-threatening disease, we present in this review a sum of the latest findings and considerations for the proper diagnosis and management of affected patients.
Money for the studynot stated
Do the authors have ties to companies?no — the authors say so
Did a manufacturer help with the study?NO
Type of studydiscussion of other studies
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Vaccine-related myocarditis (VRM) has gained attention during the global roll-out of COVID-19 vaccines. COVID-19 VRM is usually non-fatal, but factors associated with fatal outcomes remain unclear. We aimed to characterize features associated with reported fatal outcomes using a pharmacovigilance database.
Results: 31 022 reports listed COVID-19 vaccines as suspected drug; 1041 reports included myocarditis [reporting odds ratio (ROR) 31.3, 95% CI 29.0-33.8]. The median time from vaccination to myocarditis onset was 2 (1-4) days, with most events occurring within 7 days. Among reports with VRM, men accounted for the majority (77.8%) and 68.6% were ≤39 years old. Outcome data were available for 863 reports, and death was recorded in 97 reports [11.2% (95% CI, 9.3%-13.5%)]. Reported fatal outcomes were more frequent in women, patients aged ≥70 years, those with delayed onset (≥8 days after COVID-19 vaccination), and those with ≥1 comorbidities. Multivariable logistic regression identified age ≥70 years as independently associated with reported fatal outcomes (OR 8.67, 95% CI 4.41-17.3; P < .001). Older age was associated with higher odds of reported fatal outcomes among VRM reports in JADER. Female sex, delayed onset, and comorbidities were more common among reports with fatal outcomes.
Money for the studygovernment, public institutions · Japan Agency for Medical Research and Development
Do the authors have ties to companies?no — the authors say so
Did a manufacturer help with the study?NO
Type of studyobservation of people
Participants31 022
“Not stated” does not mean nobody paid — the database does not always record it.
What do orthomolecular medicine doctors write?
Orthomolecular Medicine News Service
„Even as a clinician who also received many patients in consultation from other doctors, she represented the entirety of my cases of myocarditis. And at that, the diagnosis was only a retrospective conclusion. COVID and Myocarditis Today, the active clinical cardiologist is seeing myocarditis patients on a regular basis. The scientific literature indicates that myocarditis is occurring quite frequently in patients harboring the chronic presence of the COVID-related spike protein.”Even as a clinician who also received many patients in consultation from other doctors, she represented the entirety of my cases of myocarditis. And at that, the diagnosis was only a retrospective conclusion. COVID and Myocarditis Today, the active clinical cardiologist is seeing myocarditis patients on a regular basis. The scientific literature indicates that myocarditis is occurring quite frequently in patients harboring the chronic presence of the COVID-related spike protein.
Orthomolecular Medicine News Service
„A substantial number of such patients appear to have a low-grade, smoldering myocarditis that will eventually evolve to cardiac "burnout" and a fatal congestive cardiomyopathy. This myocarditis (heart muscle inflammation) can manifest as fatigue, intermittent chest pain, shortness of breath, abnormal heart rhythms, and sometimes even the development of inflammation and blood clotting problems in the coronary arteries that can lead to heart attacks. It is vital that this inflammation gets vigorously treated and completely resolved.”A substantial number of such patients appear to have a low-grade, smoldering myocarditis that will eventually evolve to cardiac "burnout" and a fatal congestive cardiomyopathy. This myocarditis (heart muscle inflammation) can manifest as fatigue, intermittent chest pain, shortness of breath, abnormal heart rhythms, and sometimes even the development of inflammation and blood clotting problems in the coronary arteries that can lead to heart attacks. It is vital that this inflammation gets vigorously treated and completely resolved.
Orthomolecular Medicine News Service
„[100] Myocarditis, often evolving heart enlargement and heart failure, can result from the spike protein exposure following COVID vaccine(s) and/or from its persistence presence in chronic COVID. However, many cases of spike protein myocarditis, probably a substantial majority, are chronic, smoldering conditions that remain undiagnosed except when there is clear clinical evidence indicating its presence. PSP syndrome routinely involves the heart, even when not readily apparent clinically.”[100] Myocarditis, often evolving heart enlargement and heart failure, can result from the spike protein exposure following COVID vaccine(s) and/or from its persistence presence in chronic COVID. However, many cases of spike protein myocarditis, probably a substantial majority, are chronic, smoldering conditions that remain undiagnosed except when there is clear clinical evidence indicating its presence. PSP syndrome routinely involves the heart, even when not readily apparent clinically.
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.